EFFICIENCY OF TOLTERODINE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER
- Autores: Sayapova D.R1, Sitdykova M.E1
-
Afiliações:
- Edição: Nº 6 (2013)
- Páginas: 32-35
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/280013
- ID: 280013
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
The article presents the results of the examination and treatment of 30 patients with overactive bladder receiving M-anticholinergic drug tolterodine at a dose of 2 mg twice a day for 1 month. Evaluating the effectiveness of the drug was performed on the basis of the data on voiding diary, urodynamic changes, and results of ultrasound examination. The analysis showed that treatment with tolterodine within 15 days has a positive trend: normalization of urination was observed in 96,6% of patients, 76,6% of patients have reported decrease of the frequency of urgency urination, and episodes of imperative urinary incontinence decreased in 83,3% of patients. The therapy promoted the increase the duration and volume of urination, reduction of maximum uroflow rate, indicating that the effectiveness of treatment. On the 30th day of treatment, the vast majority (80%) of the patients reported improvement of their wellbeing.
Palavras-chave
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Bibliografia
- Abrams P., Cardozo I., Fall M. The standartisation of terminology of lower urinary tract function. Neurourol. Urodyn. 2002; 21; 167—178.
- Гаджиева Ж.К. Нарушения мочеиспускания: Руководство / Под ред. Ю.Г. Аляева. М.: ГЭОТАР—Медиа; 2010.
- Пушкарь Д.Ю. Гиперактивный мочевой пузырь у женщин. М.: МЕДпресс-информ, 2003. 160 с.
- Abrams P., Wein A.J. Intrduction: Overactive bladder and its treatments. Urology. 2000; 55(Suppl. 5A): 1—2.
- Балан В.Е. Урогенитальные расстройства в климактерии (клиника, диагностика, заместительная гормонотерапия). Автореф. дисс.. докт. мед. наук. М., 1998. 40 с.
- Чушков Ю.В. Комплексная диагностика и оперативное лечение больных с выпадением матки и стенок влагалища, осложненных недержанием мочи при напряжении. Дисс.. канд. мед. наук. М., 1999. 165 с.
- Савицкий Г.А., Савицкий А.Г. Недержание мочи при напряжении у женщин. СПб., 2000. 136 с.
- Пушкарев Д.Ю. Диагностика и лечение сложных и комбинированных форм недержания мочи у женщин. Дисс.. докт. мед. наук. М., 1996.
- Чечнева М.А. Клиническое значение ультразвукового исследования в диагностике стрессового недержания мочи. Автреф. дисс.. канд. мед. наук. М., 2000. 20 с.
- Groat W.C., Yoshimura N. Afferent nerve regulation of bladder function in health and disease. Handb. Exp. Pharmacol. 2009; (194): 91—138.
- Mukerji G., Yiangou Y., Grogono I. et al. localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J. Urol. 2006; 176(1): 367—373.
Arquivos suplementares
![](/img/style/loading.gif)